- Home
- PVLA vs TNXP Comparison
PVLA vs TNXP Comparison
Compare PVLA & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PVLA
- TNXP
- Stock Information
- Founded
- PVLA 2015
- TNXP 2007
- Country
- PVLA United States
- TNXP United States
- Employees
- PVLA N/A
- TNXP N/A
- Industry
- PVLA Biotechnology: Pharmaceutical Preparations
- TNXP Biotechnology: Pharmaceutical Preparations
- Sector
- PVLA Health Care
- TNXP Health Care
- Exchange
- PVLA Nasdaq
- TNXP Nasdaq
- Market Cap
- PVLA 249.2M
- TNXP 272.0M
- IPO Year
- PVLA N/A
- TNXP N/A
- Fundamental
- Price
- PVLA $25.92
- TNXP $40.87
- Analyst Decision
- PVLA Strong Buy
- TNXP Strong Buy
- Analyst Count
- PVLA 7
- TNXP 2
- Target Price
- PVLA $46.29
- TNXP $585.00
- AVG Volume (30 Days)
- PVLA 129.2K
- TNXP 720.7K
- Earning Date
- PVLA 08-15-2025
- TNXP 08-15-2025
- Dividend Yield
- PVLA N/A
- TNXP N/A
- EPS Growth
- PVLA N/A
- TNXP N/A
- EPS
- PVLA N/A
- TNXP N/A
- Revenue
- PVLA N/A
- TNXP $10,041,000.00
- Revenue This Year
- PVLA N/A
- TNXP $11.66
- Revenue Next Year
- PVLA N/A
- TNXP $793.18
- P/E Ratio
- PVLA N/A
- TNXP N/A
- Revenue Growth
- PVLA N/A
- TNXP N/A
- 52 Week Low
- PVLA $11.17
- TNXP $6.76
- 52 Week High
- PVLA $29.27
- TNXP $130.00
- Technical
- Relative Strength Index (RSI)
- PVLA N/A
- TNXP 62.15
- Support Level
- PVLA N/A
- TNXP $33.20
- Resistance Level
- PVLA N/A
- TNXP $43.80
- Average True Range (ATR)
- PVLA 0.00
- TNXP 2.63
- MACD
- PVLA 0.00
- TNXP 0.31
- Stochastic Oscillator
- PVLA 0.00
- TNXP 77.43
About PVLA Palvella Therapeutics Inc. Common Stock
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.